Open AccessBulletin of Clinical Studies in Q1 2021
Author(s) -
Yulia А. Kuznetsova,
Anna V. Smirnova
Publication year - 2021
Publication title -
zdorovʹe megapolisa
Language(s) - English
Resource type - Journals
ISSN - 2713-2617
DOI - 10.47619/2713-2617.zm.2021.v2i2;101-108
Subject(s) - clinical trial , christian ministry , pandemic , medicine , russian federation , family medicine , covid-19 , health care , disease , political science , infectious disease (medical specialty) , geography , law , regional science
Purpose. To evaluate clinical trials data since January 2021 till March 2021. Materials and methods. The information about clinical trial’s approvals from the state register of medicines of Russian Federation ministry of health website was used as the main source of the original data concerning clinical trials. The register contains all the information relating to clinical trials in Russian Federation. Results. Clinical trials data was analyzed by its type (international, local, bioequivalence), sponsorship (foreign, local), phases and disease areas. Separately COVID-19 clinical trials were considered. Conclusion. During the 2021 Q1 we can mark a clinical trail’s quantity growth (started ones) both in Russia and in Moscow in comparison with 2018-2020 similar periods, that is definitely a positive trend especially in COVID-19 pandemic circumstances. There is a significant growth of bioequivalence share in 2021 versus 2019-2020 in Moscow. Due to SARS-CoV-2 ongoing pandemic lots of related to SARS-СоV-2 treatment clinical trials started, which considerably increased the contagious diseases pool in clinical trials market structure. Totally 14 related to SARS-СоV-2 treatment trials started in Russia, including 5 ones held in Moscow Healthcare Department medical organizations.